Latest news with #Gleason
Business Wire
11 hours ago
- Business
- Business Wire
PanGIA Biotech Unveils AI-Driven Urine Test Data for Early Prostate Cancer Detection at ASCO 2025
CHICAGO--(BUSINESS WIRE)--PanGIA Biotech, a leader in non-invasive cancer diagnostics, presented findings at the 2025 Annual Meeting of the American Society of Clinical Oncology (ASCO) from a prospective, multi-center validation study evaluating its AI-powered, urine-based platform for early-stage prostate cancer detection. The study, Development and validation of an AI-enabled prediction of prostate cancer (PCa) using urine-based liquid biopsy (Abstract #3080) is the first to clinically validate PanGIA®'s novel approach pairing proprietary chemistry with machine learning. Share The study, Development and validation of an AI-enabled prediction of prostate cancer (PCa) using urine-based liquid biopsy (Abstract #3080), is the first to clinically validate PanGIA®'s novel approach—pairing proprietary chemistry with machine learning to detect cancer-specific biosignatures from a single, non-invasive urine sample. 'This study confirms what we've believed from the start: there's power in non-invasive, data-driven diagnostics,' said Holly Magliochetti, CEO of PanGIA Biotech. 'Our platform helps clinicians detect prostate cancer when intervention is most effective—without costly or invasive procedures.' Key findings presented included: Study Cohort: 197 biopsy-confirmed prostate cancer patients and 84 healthy controls. Classifier Performance: Achieved an F1 score of 0.843 with a recall of 0.967 in distinguishing cancer from non-cancer subjects. Gleason Score Cohorts: Maintained high recall (>0.89) across Gleason scores 6 through 10, with F1 scores ranging from 0.799 to 0.838. Non-Invasive Advantage: Demonstrated strong performance in detecting intermediate- and low-grade cancers, offering a less invasive alternative to traditional diagnostics. Unlike invasive biopsies or blood-based tests that often miss early-stage cases, PanGIA's approach analyzes urinary biosignatures using proprietary AI models—eliminating the need for sequencing and enabling cost-effective, globally scalable testing. Previously published in The Analyst, a journal of the Royal Society of Chemistry¹, the PanGIA platform is designed for diverse healthcare environments and holds promise for broad global adoption. About PanGIA Biotech PanGIA Biotech develops AI-integrated, urine-based liquid biopsy solutions designed for global scalability. The PanGIA® platform supports early detection, monitoring, and disease management—including cancer as early as Stage 1. With machine learning at its core, the platform deciphers biomolecular patterns to deliver accurate diagnostic insights. Backed by patents and peer-reviewed research, PanGIA is committed to reshaping healthcare through innovation. Learn more at ¹ Lim FB, et al. 'A Colorimetric Chemical Tongue Detects And Distinguishes Between Multiple Analytes.' The Analyst. 2022;147(23):5283–5292. doi:10.1039/D2AN01615J
Yahoo
11 hours ago
- Health
- Yahoo
PanGIA Biotech Unveils AI-Driven Urine Test Data for Early Prostate Cancer Detection at ASCO 2025
CHICAGO, June 02, 2025--(BUSINESS WIRE)--PanGIA Biotech, a leader in non-invasive cancer diagnostics, presented findings at the 2025 Annual Meeting of the American Society of Clinical Oncology (ASCO) from a prospective, multi-center validation study evaluating its AI-powered, urine-based platform for early-stage prostate cancer detection. The study, Development and validation of an AI-enabled prediction of prostate cancer (PCa) using urine-based liquid biopsy (Abstract #3080), is the first to clinically validate PanGIA®'s novel approach—pairing proprietary chemistry with machine learning to detect cancer-specific biosignatures from a single, non-invasive urine sample. "This study confirms what we've believed from the start: there's power in non-invasive, data-driven diagnostics," said Holly Magliochetti, CEO of PanGIA Biotech. "Our platform helps clinicians detect prostate cancer when intervention is most effective—without costly or invasive procedures." Key findings presented included: Study Cohort: 197 biopsy-confirmed prostate cancer patients and 84 healthy controls. Classifier Performance: Achieved an F1 score of 0.843 with a recall of 0.967 in distinguishing cancer from non-cancer subjects. Gleason Score Cohorts: Maintained high recall (>0.89) across Gleason scores 6 through 10, with F1 scores ranging from 0.799 to 0.838. Non-Invasive Advantage: Demonstrated strong performance in detecting intermediate- and low-grade cancers, offering a less invasive alternative to traditional diagnostics. Unlike invasive biopsies or blood-based tests that often miss early-stage cases, PanGIA's approach analyzes urinary biosignatures using proprietary AI models—eliminating the need for sequencing and enabling cost-effective, globally scalable testing. Previously published in The Analyst, a journal of the Royal Society of Chemistry¹, the PanGIA platform is designed for diverse healthcare environments and holds promise for broad global adoption. About PanGIA Biotech PanGIA Biotech develops AI-integrated, urine-based liquid biopsy solutions designed for global scalability. The PanGIA® platform supports early detection, monitoring, and disease management—including cancer as early as Stage 1. With machine learning at its core, the platform deciphers biomolecular patterns to deliver accurate diagnostic insights. Backed by patents and peer-reviewed research, PanGIA is committed to reshaping healthcare through innovation. Learn more at ¹ Lim FB, et al. "A Colorimetric Chemical Tongue Detects And Distinguishes Between Multiple Analytes." The Analyst. 2022;147(23):5283–5292. doi:10.1039/D2AN01615J View source version on Contacts Media Contact Joy CappsMedia@ 843-730-3857
Gulf Today
a day ago
- Health
- Gulf Today
Biden feeling ‘optimistic' after cancer diagnosis
Former US President Joe Biden told reporters on Friday he was feeling 'optimistic' about the future after delivering his first public remarks since revealing he had an aggressive form of prostate cancer. 'Well, the prognosis is good. You know, we're working on everything. It's moving along. So, I feel good,' Biden, 82, said after an event in Delaware belatedly marking Monday's Memorial Day federal holiday. Biden's office announced earlier this month he is battling prostate cancer with a Gleason score of nine, which places him in the most severe category. The veteran Democrat told reporters he had decided on a treatment regime, adding that 'the expectation is, we're going to be able to beat this.' 'It's not in any organ, my bones are strong, it hasn't penetrated. So I'm feeling good,' he said. The mental and physical health of the former president, the oldest person ever to hold the office, was a dominant issue in the 2024 election. After a disastrous debate performance against Trump, Biden ended his campaign for a second term. When Biden's office announced his diagnosis, they said the cancer had spread to his bones. But Biden told reporters: 'We're all optimistic about the diagnosis. As a matter of fact, one of the leading surgeons in the world is working with me.' The political row over Biden's aborted candidacy has become a major scandal since the release of the book 'Original Sin' - which alleges that Biden's White House covered up his cognitive decline while he was in office. The ex-president was asked about the controversy and responded with sarcasm, joking that 'I'm mentally incompetent and I can't walk.' He said he had no regrets about initially running for a second term, and that his Democratic critics could have challenged him but chose not to 'because I'd have beaten them.' In earlier formal remarks in New Castle, Delaware, Biden spoke of his presidency as his greatest honour, and called for better treatment of veterans. But he saved his most poignant comments to mark the 10th anniversary on May 30 of his son, National Guard veteran Beau Biden, dying of brain cancer at the age of 46. 'For the Bidens, this day is the 10th anniversary, the loss of my son Beau, who spent a year in Iraq,' said Biden, who had attended a memorial service for his son earlier in the day. 'And, to be honest, it's a hard day.' Agence France-Presse
Yahoo
2 days ago
- General
- Yahoo
Trump Says 'If You Feel Sorry' For Biden, 'Don't Feel So Sorry'
President Donald Trump launched a personal attack on Joe Biden in a nearly 5-minute ramble at a White House press conference on Friday, saying people shouldn't 'feel so sorry' for his predecessor. It began with a question from Fox News' Peter Doocy. 'So many of the things that you're trying to do are held up in court right now,' Doocy said. 'If the courts are going to have so much influence over U.S. policy, do you wish you would have just become a judge?' Both Doocy and Trump laughed after the question. The president then launched into a lengthy rambling response in which he called a federal judge in Boston 'a radical left person,' criticized the previous administration's immigration policies, praised himself and called Biden a 'vicious person.' His comments about Biden came as Trump was trying to explain why he doesn't 'believe' that Biden was truly responsible for some of his administration's policies. 'He's been a sort of a moderate person over his lifetime,' Trump said of Biden. 'Not a smart person. But a somewhat vicious person, I will say. If you feel sorry for him, don't feel so sorry, because he's vicious.' Trump added, 'He hurt a lot of people. And so, I really don't feel sorry for him.' It was not immediately clear exactly what Trump was referring to when he said he didn't 'feel sorry' for Biden. However, manynewsoutlets and people on social media noted that the comments came off as particularly insensitive in the wake of the former president's cancer diagnosis. Biden's office announced this month that he had been diagnosed with aggressive stage 4 prostate cancer, but told reporters at his Delaware home on Friday that 'the prognosis is good.' 'The expectation is we're going to be able to beat this,' Biden said After the news broke, Biden was met with an outpouring of support and encouragement, including from people in Trump's cabinet. Others, including Donald Trump Jr. and far-right influencerLaura Loomer, took his illness as an opportunity to attack him. Trump himself initially posted a sympathetic message on Truth Social, writing, 'Melania and I are saddened to hear about Joe Biden's recent medical diagnosis.' But he later played into unverified theories that Biden had hidden his cancer diagnosis. 'Actually, I'm surprised that, you know, the public wasn't notified a long time ago because to get to stage 9, that's a long time,' Trump told reporters last week. (Biden has stage 4 cancer with a Gleason score of 9.) The president also stated, 'somebody is not telling the facts.' Biden On His Cancer Diagnosis: 'We're Going To Be Able To Beat This' Biden Speaks Publicly For First Time Since Cancer Announcement Biden Had Not Received Prostate Cancer Screening Since 2014, Spokesperson Says
Yahoo
2 days ago
- General
- Yahoo
Biden diagnosed with aggressive prostate cancer
When you buy through links on our articles, Future and its syndication partners may earn a commission. Former President Joe Biden was diagnosed with an "aggressive" form of prostate cancer that has spread to his bones, his office said Sunday. Biden, 82, received the diagnosis on Friday and he and his family are "reviewing treatment options." Biden's office said his cancer was given a Gleason score of 9, with 10 being the most malignant. "While this represents a more aggressive form of the disease, the cancer appears to be hormone-sensitive which allows for effective management," the statement said. Once it has metastasized to the bones, "it's very treatable, but not curable," Dr. Matthew Smith of Massachusetts General Brigham Cancer Center told The Associated Press. Cancer and tragedy have been a "recurring part of Biden's personal and political life," The Washington Post said. He "dedicated much of his later career to cancer research after losing his son Beau to brain cancer in 2015." When launching his 2022 "cancer moonshot" to halve the U.S. cancer death rate over 25 years, Biden said it could be an "American moment to prove to ourselves and, quite frankly, the world that we can do really big things." Thanks to prostate cancer treatments developed in the past few years, "life is measured in years now, not months," University of Washington specialist Dr. Daniel Lin told The New York Times. People with metastatic prostate cancer "can live 5, 7, 10 or more years," said Dr. Judd Moul at Duke University. So an octagenarian like Biden "could hopefully pass away from natural causes and not from prostate cancer."
